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OBJECTIVES The aim of this study was to close muscular ventricular septal defects (MVSDs) in children,
with a new device, the Amplatzer ventricular septal defect occluder (AVSDO).
BACKGROUND The design of previously used devices for transcatheter closure of MVSDs is not ideal for this
purpose and their use has been limited by several drawbacks.
METHODS Six patients, aged 3 to 10 years, with MVSDs underwent transcatheter closure using the
AVSDO. The device is a modified self-centering and repositionable Amplatzer device that
consists of two low profile disks made of Nitinol wire mesh with a 7-mm connecting waist.
The prosthesis size (connecting waist diameter) was chosen according to the measured
balloon stretched VSD diameters. A 6-F or 7-F sheath was used for the delivery of the
AVSDO. Fluoroscopy and transesophageal echocardiography were utilized for optimal
guidance.
RESULTS The location of the defect was midmuscular in five patients and beneath the pulmonary valve
in one. The balloon stretched MVSD diameter ranged from 6 to 11 mm. Device placement
was successful in all patients, and complete occlusion occurred in all six patients (95%
confidence interval 54.06% to 100%). Two patients developed transient complete left bundle
branch block. No other complications were observed.
CONCLUSIONS This encouraging initial clinical success indicates that the AVSDO is a promising device for
transcatheter closure of MVSDs in children. Further clinical trials and longer follow-up are
needed before the widespread use of this technique can be recommended. (J Am Coll Cardiol
1999;33:1395–9) © 1999 by the American College of Cardiology
Surgical repair of congenital muscular ventricular septal
defects (MVSDs) has been associated with considerable
morbidity and mortality (1). As an alternative to surgery a
variety of devices have been used for transcatheter closure of
congenital or postmyocardial infarction MVSDs (2–5).
However, these devices were not originally designed for this
purpose, and their widespread use has been limited by
several drawbacks such as large delivery sheaths, inability to
recapture and reposition and a very high rate of residual
shunts (2–4). The Amplatzer ventricular septal occluder is a
new device especially designed for transcatheter closure of
defects of the muscular ventricular septum which has been
successfully tested in animal and in vivo experimental
studies (6). In this report we present the first clinical
applications in children.
METHODS
Device design. The presented device is a modified Am-
platzer atrial septal defect (ASD) occluder (7,8), which is
self-centering and repositionable after deployment and has a
low profile. It is constructed of 0.004-in. (0.01 cm) Nitinol
wires, tightly woven into two self-expandable flat round
disks with a 7-mm connecting waist corresponding approx-
imately to the thickness of the muscular ventricular septum
(Fig. 1). Dacron fabric is sewn into both retention disks as
well as into the waist. Waist diameters vary from 6 to
14 mm. The left ventricular retention skirt is 4 mm larger
than the waist, and the right ventricular retention skirt is
only 3 mm larger than the waist. The device is securely
fastened onto a delivery cable by a recessed screw. It is
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loaded into a long 6-F or 7-F (occluders larger than 6 mm)
delivery sheath.
Patient population. Between November 1997 and May
1998, six patients aged 3 to 10 years with MVSDs were
subjected to transcatheter closure with the Amplatzer
muscular VSD occluder (AGA Medical Corporation,
Golden Valley, Minnesota). In all patients VSD closure was
indicated for hemodynamic or other medical reasons. In-
formed consent was obtained in each case, and devices were
implanted under a research protocol approved by the Ethical
Committee of “Aghia Sophia” Children’s Hospital of
Athens.
Study design. Patients were screened by conventional trans-
thoracic two-dimensional echocardiography with multiple
subxyphoid, apical and parasternal views. Two patients with
suboptimal transthoracic echocardiographic examination
were further evaluated with biplane transesophageal and
color Doppler echocardiography. Two patients had under-
gone diagnostic cardiac catheterization and angiography
three and six months before transcatheter closure. Patient
inclusion criteria were: a) maximal VSD diameter less than
12 mm; b) a distance of .5 mm from the margins of the
defect to the aortic, mitral and tricuspid valves; c) single or
main central (in cases of multiple Swiss cheese type defects)
opening into the right ventricular cavity, and d) left to right
shunt across the defect with left ventricular enlargement.
Procedure. The technique of transcatheter closure of
MVSDs used was similar to that described by Lock et al.
(2,3). The patients were intubated and under general
anesthesia underwent right and left heart catheterization.
The location and size, number of defects and their relation
to the surrounding structures were defined by angled angio-
graphic views. Five patients had a single midmuscular (Fig.
2A) and one patient an outlet muscular (Fig. 3A) VSD. In
the five patients with the midmuscular VSDs a retrograde
arterial catheter (4 to 5 F Cobra type I, Cordis) was passed
from the left ventricle to right ventricle. This was facilitated
by small hand injections of contrast medium, through a
second arterial catheter (4- to 5-F Pigtail, Gordis) that was
Abbreviations and Acronyms
ASD 5 atrial septal defect
MVSDs 5 muscular ventricular septal defects
Qp/Qs 5 pulmonary/systemic flow ratio
SPAP 5 systolic pulmonary artery pressure
TEE 5 transesophageal echocardiography
TGA 5 transposition of the great arteries
Figure 1. Side view of the Amplatzer muscular ventricular septal
defect occluder made of woven 0.004-in. (0.01 cm) Nitinol wires
into two flat disks with a 7-mm connecting waist. The left
ventricular disk is on the right and the right ventricular disk is on
the left of the panel.
Figure 2. Steps of transcatheter muscular ventricular septal defect
closure with modified Amplatz device. (A) Long axial oblique left
ventriculogram obtained from Patient 4, demonstrating a midmus-
cular ventricular septal defect (arrowheads). (B) Hand injection of
contrast medium into the left ventricle showing an appropriately
positioned left ventricular disk. (C) Deployment of the right
ventricular disk. (D) Long axial oblique left ventriculogram after
release of the device, showing complete closure of the defect.
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introduced from the opposite femoral artery. Through the
Cobra catheter a soft J-tipped 260-cm exchange 0.032- to
0.035-in. (0.08 to 0.09 cm) guide wire was advanced into
the pulmonary artery, where it was snared from a percuta-
neous jugular approach. Then the catheter was removed and
a 7-F (6 F in one patient) long transseptal sheath was
advanced over the wire from the jugular vein to the left
ventricle. In the patient with the outlet VSD a 7-F balloon-
tipped end-hole catheter was introduced into the right
ventricle from the femoral vein and exchanged for the 7-F
delivery sheath. All patients underwent balloon sizing to
establish the “stretched” diameter of the defect (2). The
device size (waist diameter) was selected to be equal to the
measured “stretched” diameter (2). The device was screwed
to the tip of the delivery cable and collapsed into a loader as
previously described (7,8). The collapsed device was then
advanced into the guiding catheter by pushing the delivery
cable. Under fluoroscopic and transesophageal ultrasonic
guidance, the left ventricular disk was deployed and pulled
gently against the septum, which was both felt and observed
by transesophageal echocardiography (TEE) and angiocar-
diography (Fig. 2B). Then the sheath was pulled back and
the right ventricular disk was deployed (Fig. 2C). The
device was released only when its position was optimal and
interference with atrioventricular valve structures had been
excluded by TEE with color flow Doppler (Fig. 4). After
release of the device both color Doppler echocardiography
and left ventriculography were performed to detect residual
shunts (Figs. 2D and 3B). All patients were discharged on
the day after the procedure on aspirin 3 to 5 mg/kg daily for
six months.
All patients had a chest X-ray and a transthoracic color
Figure 3. Left ventriculogram in a four-chamber view obtained from patient 1 with corrected transposition of the great arteries and an
outlet ventricular septal defect (arrowheads), before (A) and after (B) device placement. Complete closure of the defect has been achieved.
Figure 4. Transesophageal two-dimensional and color Doppler obtained from four-chamber view immediately after implantation of the
Amplatzer prosthesis. Note good position of the device with no evidence of residual shunt. LA 5 left atrium; LV 5 left ventricle; LVD 5
left ventricular disk; RA 5 right atrium; RV 5 right ventricle; RVD 5 right ventricular disk.
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Doppler echocardiographic study at 24 h after the procedure
and at 1 and 3 months later. A transesophageal echocardio-
graphic study was scheduled for the 6-month follow-up.
Persistent shunts were angiocardiographically and echocar-
diographically graded as foaming, trivial, small, moderate
and large as previously described (7,8).
RESULTS
Patient characteristics and outcome after device placement
are summarized in Table 1. The balloon “stretched” diam-
eters ranged from 6 to 11 mm (mean 5 9.3). The angio-
graphic defect diameters ranged from 5 to 9 mm (mean 5
7.3) and the thickness of the muscular ventricular septum
from 5 to 6.5 mm (mean 5 5.5). Pulmonary/systemic flow
ratio (Qp/Qs) varied from 1.7 to 2.5 (mean 5 2.1). Systolic
pulmonary artery pressure (SPAP) was normal in all pa-
tients with midmuscular VSDs. Patient 1 had corrected
transposition of the great arteries (TGA) with an outlet
VSD, but despite the presence of a mild to moderate
subpulmonary stenosis (peak systolic pressure gradient 5
40 mm Hg) he had a significant left to right shunt
(Qp/Qs 5 2.2:1) and a SPAP of 60 mm Hg. After
administration of 100% oxygen, the SPAP was reduced to
40 mm Hg and the Qp/Qs increased to 2.7:1. Patient 3 had
a small to moderate VSD (Qp/Qs 5 1.7) and two episodes
of subacute infective endocarditis. During the last episode
he had a suspected cerebral embolic event with emesis and
severe headache. Surgical closure was suggested after this
episode, but it was refused by the parents.
Device delivery was successful and associated with com-
plete occlusion in all six patients (100% closure rate, 95%
confidence interval 54.06% to 100%) (Figs. 2D and 3B).
Foaming was present in two patients but disappeared within
15 to 20 min. Misplacement of one disk into the right
ventricle occurred in one patient and was successfully
managed by recapturing the device in the delivery sheath
and redeploying it. During the procedure two patients
developed complete left bundle branch block, which re-
solved within 12 h. No other complications were observed.
Fluoroscopy and total procedural times ranged from 34 to
57 min (mean 5 47 min) and from 122 to 155 min (mean 5
138 min), respectively.
Follow-up echocardiographic data were available in all six
patients at one and three months after the procedure. There
was no evidence of residual shunts. The device was in an
appropriate position and no interference with the adjacent
cardiac structures was observed. Metal fatigue fractures on
chest radiography were not observed. The patient with the
corrected TGA and the outlet VSD underwent cardiac
catheterization three months after the transcatheter closure
which showed a normal for age pulmonary artery pressure
(35 mm Hg) and a peak subpulmonary pressure gradient of
35 mm Hg. Angiography did not reveal an increase of the
subpulmonary obstruction.
DISCUSSION
Transcatheter closure of MVSDs with the Rashkind double
umbrella was first described by Lock et al. in 1988 (2).
Subsequently, the Lock clamshell occluder (3,4) and very
recently the Sideris buttoned device (5) have been used for
nonsurgical closure of MVSDs, but have not always per-
formed at their expectations. The Rashkind double umbrella
was originally designed for closure of a persistent patent
ductus arteriosus and the clamshell occluder as well as the
buttoned device for occlusion of ASDs. Therefore, their
shape and design are not ideal for transcatheter closure of
MVSDs. The major limitations of these devices include
large delivery systems limiting their use in infancy with risk
for vascular injury, complex implantation techniques, inabil-
ity of repositioning and redeployment and significant resid-
ual shunts (3–5). Kumar et al. reported his experience with
closure of apical muscular VSDs in 10 patients using the
clamshell device and the incidence of residual shunts was
100% (4). Apparently the umbrella type device does not
provide complete closure.
Comparison with other devices. The findings of this
study, which represents the first human experience, indicate
that transcatheter closure of single MVSDs with the Am-
platzer VSD occluder is feasible, effective and safe. Com-
plete occlusion was obtained in all patients with no signif-
icant complications during the procedure or at short-term
follow-up. The device used is a novel modification of the
Amplatzer ASD occluder which offers significant advan-
tages over the previously used devices: 1) it is delivered
Table 1. Patient Characteristics and Outcome After Device Placement
Patient
No.
Age
(yr)
Weight
(kg) Diagnosis
“Stretched” VSD
Diameter (mm) Outcome Complications
1 3 14 CTGA, SubPS, outlet VSD 11 Complete closure TCLBBB
2 3.5 15 Midmuscular VSD 11 Complete closure TCLBBB
3 5 18 Midmuscular VSD 6 Complete closure None
4 10 33 Midmuscular VSD 11 Complete closure None
5 7 30 Midmuscular VSD 8 Complete closure None
6 6 25 Midmuscular VSD 9 Complete closure None
CTGA 5 corrected transposition of the great arteries; SubPS 5 subpulmonary stenosis; TCLBBB 5 transient complete left bundle branch block; VSD 5 ventricular septal
defect.
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through a 6- to 7-F sheath, which allows its use even in
small infants; 2) its long connecting waist fits within the
communication forcing the blood to pass through a channel
filled with thrombogenic polyester material, and therefore
closure by thrombosis should be virtually 100%; 3) it
possesses low profile small retention disks to lower the risk
of encroachment on vital cardiac structures, and 4) it can be
easily repositioned and redeployed several times. Although
we did not encounter all anatomic types of MVSDs, such as
apical or multiple defects, we believe that these communi-
cations will be amenable to transcatheter closure with this
device. The other issue to be addressed is the thickness of
the muscular ventricular septum. Based on measurements
we previously made in normal hearts the diameter of most
muscular ventricular septa varied from 4 to 6.5 mm (unpub-
lished data). Therefore, the 7-mm standard waist length of
the Amplatzer VSD occluder is suitable for the vast majority
of the patients. If the device protrudes slightly into the
ventricles it is completely immaterial as full endothelializa-
tion will occur. However, septa much thicker than 7 mm
would be unsuitable until modifications of the prosthesis are
available. No patient in this study had a ventricular septal
thickness greater than 7 mm, in which case it would
potentially cause problems of overelongation of the device.
Precise measurement of the defect size is critical for
successful closure. Since the anatomy of several MVSDs is
complex the echocardiographic and angiographic estimation
of the defect diameter may be misleading. Typically these
defects change their size during systole and diastole and are
therefore difficult to measure. Therefore, the selection of the
device diameter according to the balloon “stretched” diam-
eter of the MVSD is of paramount importance to achieve
complete occlusion and prevent device dislodgement and
embolization. This maneuver also allows precise localization
of the communication and reconfirms catheter passage
through its main channel (2). Nevertheless, echocardio-
graphic evaluation before closure remains essential to map
the VSD location, demonstrate additional defects and
determine the overall suitability for transcatheter closure.
Transesophageal and color Doppler echocardiography play
a very important role in guiding the deployment of the
device and the assessment of results (9).
Conclusions. The Amplatzer VSD occluder appears to be
a promising device for the transcatheter closure of MVSDs
in children. But before this technique enters routine clinical
practice, further studies are required to document its effi-
cacy, safety and long-term results in a larger number of
patients.
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